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Abstract
Demographic changes and a more active life-style in older age have contributed to an increasing public awareness of
the need for lifelong vaccination. Currently many older persons have been vaccinated against selected pathogens
during childhood but lack regular booster immunizations. The impact of regular vaccinations when started late in life
was analyzed in an open, explorative trial by evaluating the immune response against tetanus and diphtheria in
healthy  older  individuals.  252  persons  aged  above  60  years  received  a  booster  vaccination  against  tetanus,
diphtheria, pertussis and polio and a subcohort (n=87) was recruited to receive a second booster vaccination against
tetanus, diphtheria and pertussis 5 years later. The percentage of unprotected individuals at the time of enrollment
differed substantially for tetanus (12%) and diphtheria (65%). Despite protective antibody concentrations 4 weeks
after  the  first  vaccination  in  almost  all  vaccinees,  antibodies  had  again  dropped  below  protective  levels  in  10%
(tetanus) and 45% (diphtheria) of the cohort after 5 years. Protection was restored in almost all vaccinees after the
second vaccination. No correlation between tetanus- and diphtheria-specific responses was observed, and antibody
concentrations were not associated with age-related changes in the T cell repertoire, inflammatory parameters, or
CMV-seropositivity suggesting that there was no general biological “non-responder type.” Post-vaccination antibody
concentrations  depended  on  pre-existing  plasma  cells  and  B  cell  memory  as  indicated  by  a  strong  positive
relationship between post-vaccination antibodies and pre-vaccination antibodies as well as antibody-secreting cells.
In contrast, antigen-specific T cell responses were not or only weakly associated with antibody concentrations. In
conclusion, our findings demonstrate that single shot vaccinations against tetanus and/or diphtheria do not lead to
long-lasting immunity in many elderly persons despite administration at relatively short intervals. Sufficient antigen-
specific B cell memory B generated by adequate priming and consecutive booster vaccinations and/or exposure is a
prerequisite for long-term protection.
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Introduction
Between 1990 and 2010, the percentage of persons aged 65
years or over has risen from 13.9% to 17.4% in the European
population  (EU-27)  and  is  estimated  to  reach  30%  by  2060
(European  Commission,  Demography  Report  2010.  http://
ec.europa.eu/eurostat). The topic of vaccination in old age has
received increasing attention in the last years resulting in new
vaccination recommendations for the elderly in many countries
[1,2]. Older persons are enjoying an increasingly active lifestyle
PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e82967leading  to  changes  in  their  medical  needs  including  their
awareness of the importance of vaccination. Vaccines against
influenza, pneumococcal disease or herpes zoster are not only
an effective measure to prevent severe disease and mortality,
but  can  also  be  a  measure  to  ensure  quality  of  life  and
independence.  Presently,  consensus  is  arising  that  regular
vaccinations over the whole lifetime would be optimal [1,3–5].
This concept is still far away from reality, in particular for the
generation over 60 years of age. Vaccination against tetanus
has been available since the 1920s and most older persons
have  been  vaccinated  against  tetanus  during  childhood.
However, it has been shown that the number of vaccine doses
received in life decreases with age. In a study conducted in
France adults under the age of 30 years were shown to have
received  on  average  7.1  (95%CI  6.9-7.2)  doses  of  tetanus
vaccine,  which  corresponds  well  with  recommendations  of  5
doses  during  childhood/adolescence  and  10-year  booster
intervals in many countries. However, persons aged 50 to 60
years  received  only  5.7  (95%CI  4.6-6.8)  during  their  lifetime
indicating that booster vaccination was not regularly performed
[6].  Whereas  neonatal  tetanus  has  virtually  disappeared  in
Europe (0-7 cases per year from 2007-2011 compared to 69
and 27 in 1990 and 2000, respectively), there are still 100-200
cases of tetanus infection reported in Europe per year, mainly
in adults over the age of 50 years (data from 2007-2011) [7].
Similar  data  have  been  obtained  for  the  usage  of  diphtheria
vaccine in persons up to 60 years of age in France with slightly
lower numbers of vaccines doses during life-time compared to
young  adults  [6].  However,  recommendations  regarding
vaccination against diphtheria varied greatly in the last century
and  vaccination  was  presumably  not  performed  during  and
shortly after World War II. Therefore persons born in the 1940s
might  frequently  not  have  received  appropriate  childhood
vaccination.  Vaccination  recommendations  differ  between
European countries, but there is consensus that tetanus and
diphtheria  vaccination  should  be  applied  using  a  combined
vaccine.  In  several  countries  pertussis  is  included  as  an
additional  antigen  in  combination  vaccines.  In  many  cases,
vaccination history is better documented for tetanus than for
diphtheria, and the time point for booster vaccination is based
on  the  last  tetanus  vaccination.  In  the  summary  of  product
characteristics of combination vaccines containing tetanus and
diphtheria  toxoid  administration  of  three  doses  in  a  primary
schedule is described for persons in whom the last vaccination
dates back more than 20 years. However, in clinical practice
this  is  rarely  done.  We  and  others  have  demonstrated
decreased  antibody  concentration  and  lack  of  protection
against  tetanus  and  diphtheria  in  old  age  [8–12].  We  also
demonstrated that protection was relatively short lasting in old
age [13]. The goal of this study was therefore to investigate the
level of protection against tetanus and diphtheria in the elderly
population and to analyze the immune response to tetanus and
diphtheria following two doses of vaccine applied at a 5-years
interval.  A  cohort  of  252  persons  aged  60  years  or  older
received  a  booster  vaccination  against  tetanus,  diphtheria,
pertussis  and  polio.  The  results  of  this  study  have  been
published  previously  [14].  For  the  current  study  87  persons
from  this  cohort  were  recruited  to  receive  a  second  booster
vaccination  five  years  later.  In  accordance  with  national
vaccination guidelines the second booster vaccination did not
include  polio  antigen.  As  vaccination  history  is  very
heterogeneous  for  pertussis  and  natural  exposure  is  more
likely for this pathogen we chose to investigate only tetanus-
and diphtheria-specific immune responses. Thereby we aimed
to evaluate the impact of regular vaccinations in old age in a
“real-life”  cohort  with  presumably  frequently  inadequate
vaccination  history.  We  demonstrate  that  the  chosen
immunization strategy does not lead to long lasting immunity in
many elderly persons due to a too small memory B cell/plasma
cell pool.
Materials and Methods
Study cohort
The  protocol  for  this  trial  and  a  supporting  CONSORT
checklist are available as supporting information; see Protocol
S1 and Checklist S1.
The  original  study  cohort  included  252  healthy,  elderly
volunteers (median age 66y, range 59-91y; 116 females) who
received  a  booster  vaccination  against  tetanus,  diphtheria,
pertussis and polio (Repevax®, sanofi pasteur MSD). Antibody
concentrations  against  all  components  of  the  vaccine  were
determined  prior  to  and  4  weeks  after  vaccination  and  the
results  have  been  previously  published  [14].  For  the  current
study  a  subcohort  of  87  persons  received  a  second  booster
vaccination (Boostrix® 0.5ml, Glaxo Smith Kline) 5 years later
(recruitment: January 2010-April 2010; follow-up: 4 weeks after
vaccination).  In  accordance  with  Austrian  vaccine
recommendations [15], the second vaccination did not include
polio antigens. Both vaccines are commercially available and
contain  aluminum  phosphate  and  aluminum  hydroxide  as  an
adjuvant.  Figure  1  shows  the  CONSORT  flow  chart  for  the
study.  For  the  current  study  report  serum  samples  obtained
before and after the first vaccination were re-tested for the 87
persons  receiving  the  second  vaccination  in  order  to  ensure
comparability  of  the  methods.  The  antibody  concentrations
obtained in the re-testing corresponded well with the original
data  (Spearman  correlation:  tetanus:  rs=0.878.  and  rs=0.841.
pre-  and  post-vaccination;  diphtheria:  rs=0.895  and  rs=0.905
pre- and post-vaccination; p<0.0001 for all correlations). Self-
reported  vaccination  history  at  the  time  of  the  first  study
enrollment was heterogeneous and is summarized in Table 1.
Persons with chronic viral infection (Human Immunodeficiency
virus, Hepatitis B virus, Hepatitis C virus), transplant recipients
and patients under immunosuppressive or chemotherapy were
not included in the study. Routine laboratory parameters (liver
and  kidney  function,  blood  count)  were  determined  and  all
participants  were  shown  to  be  in  good  health.  No  serious
adverse  events  occurred  after  vaccination.  The  primary
objective of the study was to compare vaccine-induced immune
responses in young versus elderly adults. This comparison is
subject of a separate publication currently in preparation. The
results  presented  here  cover  the  secondary  objective  of  the
study,  which  was  to  identify  factors  influencing  vaccination
outcome.
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doi: 10.1371/journal.pone.0082967.g001
Table  1.  Self-reported  vaccination  history  at  the  time  of
enrollment.
Tetanus time since last vaccination known n=78
10.1 ± 5.2
years
 
time since last vaccination
unknown
n=9 -
Diphtheria time since last vaccination known n=41
15.1 ±17.1
years
 
time since last vaccination
unknown
n=46 -
Tetanus/
Diphtheria
simultaneously
n=27
(31%)
 
The number of participants for whom the time point of the last vaccination was
known  or  unknown  known  is  indicated.  The  mean  time  ±  SD  since  the  last
vaccination  is  given  in  years.  The  number  and  percentage  of  persons,  who
received  their  last  vaccination  against  tetanus  and  diphtheria  as  a  combined
vaccine, are indicated.
doi: 10.1371/journal.pone.0082967.t001
Ethics statement
Both studies were approved by the local ethics committee
(Medical University, Innsbruck, Austria) and in accordance with
changes in the legal requirements the second vaccination was
registered at the EU Clinical Trials Register (EU-CTR) as an
open  exploratory  Phase  4  clinical  trial  with  the  EUDRACT
number  2009-011742-26.  All  participants  gave  their  written
informed consent.
Determination of antibody concentrations
Microtiter  plates  were  coated  with  1µg/ml  tetanus  or
diphtheria  toxoid  (Statens  Serum  Institute)  and  blocked  with
0.01M  Glycin.  Serum  samples  were  tested  in  duplicates.
Peroxidase-labeled rabbit anti-human IgG (Chemicon/Millipore)
antibody was used as secondary antibody. IgG antibodies were
quantified in IU/ml using standard human anti-tetanus and anti-
diphtheria sera (NIBSC). The detection limit of the assays used
was 0.01 IU/ml and values below the limit of detection were set
to 0.005 IU/ml for calculation of geometric mean concentrations
(GMC).  Antibody  concentrations  above  0.1  IU/ml  were
considered as protective.
Antibodies against Cytomegalovirus (CMV) were determined
using a commercially available ELISA Kit (Siemens).
Detection of antigen-specific antibody secreting cells
ELISPOT assays for detection of antigen-specific antibody-
secreting  cells  were  performed  following  manufacturer´s
instructions (Mabtech). Briefly, PVDF-membrane 96-well plates
(MAIPS4510, Millipore) were pre-wetted with 70% ethanol and
coated  over  night  with  10µg/ml  anti-IgG  antibody  (Mabtech).
500.000 peripheral blood mononuclear cells (PBMC) per well
were cultivated for 24h. Detection of antigen-specific antibody-
producing  cells  was  performed  using  0.05µg/ml  tetanus  or
diphtheria  toxoid  (1.5h,  37°C),  which  had  been  biotinylated
using  the  EZ-Link  Sulfo-NHS-LC-Biotinylation  Kit  (Pierce).
Detection  was  performed  using  Streptavidin  coupled  with
alkaline phosphatase (1.5h, RT) and the colorimetric substrate
BCIP/NBT  (Moss  Inc.).  Spots  were  counted  using  a  Zeiss
Elispot  Reader.  Detection  with  biotinylated  bovine  serum
albumin was used as a negative control.
Detection of antigen-specific cytokine secreting T cells
ELISPOT  assays  for  detection  of  antigen-specific  T  cells
secreting Interferon (IFN)-γ or Interleukin (IL)5 were performed
following manufacturer´s instructions (Mabtech). Briefly, PVDF-
membrane  96-well  plates  (MAIPS4510,  Millipore)  were  pre-
wetted  with  70%  ethanol  and  coated  over  night  with  5µg/ml
anti-IFN-γ or anti-IL-5 antibody (Mabtech). 500.000 PBMC per
well  were  cultivated  for  24h  (IFN-γ)  or  48h  (IL-5)  in  the
presence of 5µg/ml tetanus or diphtheria toxoid. Detection of
secreted  cytokines  was  performed  by  adding  1µg/ml
biotinylated  anti-INF-γ  or  anti-IL-5  antibody  (Mabtech,  1.5h,
37°C).  Detection  was  performed  using  Streptavidin  coupled
with  alkaline  phosphatase  (1.5h,  RT)  and  the  colorimetric
substrate BCIP/NBT (Moss Inc.). Spots were counted using a
Zeiss Elispot Reader. PBMC cultured without antigen served
as a negative control.
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PBMC  were  washed  with  PBS  and  stained  with  anti-CD3-
PE-Cy7 (Biolegend), anti-CD4-PerCP (BD Pharmingen), anti-
CD8-PE  (BD  Pharmingen),  anti  CD28-APC  (Biolegend),and
anti  CD45RO-(FITC  (BD  Pharmingen)  antibodies  for  20  min,
4°C in the dark. After washing with PBS, cells were analyzed
using  a  FACS  Canto  II  cytometer  and  FACSDiva  software
(BD). T cells were gated as CD3+CD4+ or CD3+CD8+ and naïve
(CD28+CD45RO-),  memory  (CD28+CD45RO+)  and  effector
(CD28-) subpopulations were defined.
Quantification of IL-6 and IL-10 in serum
Serum  concentrations  of  Interleukin  (IL)-6  and  IL-10  were
determined  by  commercially  available  ELISA  Kits  (Mabtech)
following manufacturer´s instructions.
Determination of neopterin, kynurenine, tryptophan and
CRP
Tryptophan and kynurenine concentrations were determined
by HPLC on the same day using a reversed-phase C18 column,
0.015 mol/l acetic acid/sodium acetate buffer and a flow-rate of
1  ml/min  as  described  earlier  [16,17].  Tryptophan  was
monitored by its native fluorescence at 285 nm excitation and
360 nm emission wavelengths, kynurenine was determined by
UV  absorption  detection  at  360  nm  wavelength,  and  the
kynurenine to tryptophan ratio (Kyn/Trp) was calculated as an
estimate  of  the  tryptophan  breakdown  rate.  Serum  neopterin
concentrations were measured using a competitive ELISA with
a  sensitivity  of  2  nmol/l  (Brahms).  The  concentration  of  C-
reactive  protein  (CRP)  in  serum  was  determined  by  a
diagnostic laboratory using a turbidimetric method.
Statistical analysis
Continuous variables are expressed as median and range as
well  as  means  ±  standard  deviation.  The  Spearman’s  rank
correlation coefficient was calculated to determine relationships
between  tetanus-  and  diphtheria-specific  antibody
concentrations  and  other  baseline  characteristics  prior  to
vaccination with concentrations after vaccination and changes
in  concentration  during  follow-up.  Scatterplots  were  used  to
show the relationship patterns. Correlations between tetanus-
and  diphtheria-specific  responses  were  also  analyzed  using
Spearman´s  rank  correlation  coefficients.  In  order  to  explore
general biological “non-responder phenotypes”, dependence of
antibody concentrations with age-related changes in the T cell
repertoire  and  inflammatory  parameters  were  examined  by
Spearman´s rank correlation coefficients. Antibody responses
in  CMV-seropositive  and  CMV-seronegative  persons  were
compared by Mann-Whitney U-test. A two-sided p-value of less
than 0.01 was considered to indicate statistical significance. All
statistical analyses were performed using the software package
SPSS version 11 (SPSS Inc., Chicago, US).
Results
Level of protection against tetanus and diphtheria in
elderly vaccinees
Antibody  concentrations  were  determined  prior  to  and  28
days after each of two vaccinations, which were administered
at a five-year interval. For tetanus we found that 12% of the
cohort had antibody concentrations below 0.1 IU/ml prior to the
first vaccination (Figure 2A). Four weeks after the vaccination
all  participants  developed  antibody  concentrations  above  the
protective limit of 0.1 IU/ml. Over the 5-year interval until the
second vaccination antibody concentrations dropped under the
protective  limit  in  10%  of  the  participants  and  again  all
vaccinees developed antibody concentrations above 0.1IU/ml
four  weeks  after  the  second  vaccination.  For  diphtheria,  our
results demonstrated that 65% of the participants did not have
protective antibody concentrations prior to the first vaccination
(Figure  2B).  The  majority  of  these  persons  developed
protective  antibodies,  but  11%  of  the  vaccinees  still  had  no
protective  antibody  concentrations  four  weeks  after  the  first
vaccination.  Over  the  5-year  interval  (i.e.,  between  the  two
vaccinations),  antibody  concentrations  declined  below
protective levels in a large portion of the participants, leaving
45%  without  protective  antibodies  prior  to  the  second
vaccination. Four weeks after the second booster vaccination,
6% of the vaccinees still had no protective antibodies. These
results demonstrate that the levels of protection against tetanus
and  diphtheria  differ  substantially  in  the  older  population.
Despite the fact that even with very low or undetectable pre-
vaccination antibody titers most older persons mount protective
immune  responses  to  tetanus  and  diphtheria  after  a  single
shot, the duration of the protection is short in a large proportion
of the cohort, particularly in the case of diphtheria.
Correlations of antibody concentrations after the first
and second vaccination
We  next  wanted  to  define  whether  there  were  consistent
responders/non-responders  to  tetanus-  and/or  diphtheria-
vaccination. We first correlated antibody concentrations before
the first with the ones before the second vaccination. Figure 3A
shows that the antibody concentrations prior to the first shot
were highly correlated with the antibody concentration prior to
the  second  vaccination  for  both  tetanus  and  diphtheria
(p<0.0001). This relationship was also observed when antibody
concentrations after the first and after the second vaccination
were compared (p=0.011 for tetanus; p<0.0001 for diphtheria)
(Figure  3B).  This  suggests  a  persistent  high-responder/low-
responder pattern. In the case of diphtheria 40% of the cohort
did not have protective antibody concentrations, neither before
the first nor before the second vaccination (indicated grey in
Figure 3A). Five of these persons were additionally unable to
raise a protective immune response against diphtheria, neither
after  the  first  nor  the  second  vaccination  (indicated  grey  in
Figure 3B).
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not linked
In  order  to  define  whether  there  was  a  “non-responder
phenotype”  defined  by  a  general  inability  of  certain  elderly
persons  to  respond  properly  to  vaccination,  we  correlated
antibody concentrations to tetanus and diphtheria prior to and
after both vaccinations.
Figure  4  demonstrates  that  there  was  no  statistically
significant relationship between tetanus- and diphtheria-specific
antibody concentrations before and after the first vaccination
(p=0.166  pre-vaccination;  p=0.879  post-vaccination).
Correlations  between  tetanus-  and  diphtheria-specific
antibodies  are  slightly  more  pronounced  for  the  second
vaccination suggesting a certain degree of synchronization, but
still  do  not  reach  statistical  significance  (p=0.082  pre-
vaccination;  p=0.060  post-vaccination).  These  results  show
that there is no general non-responder type but that inability to
respond seems to be linked to a certain antigen. Parameters
used as indicators of biological aging of the immune system
[18–25]  did  also  not  correlate  with  antibody  concentrations
before and after vaccination. Specifically we measured CD4+
and CD8+ naïve, memory and effector T cell counts, neopterin,
the kynurenin/tryptophan ratio in serum, as well as parameters
of inflammation (“inflammaging”) [26], such as IL-6, IL-10, and
CRP (Table 2). In addition, there was no difference in antibody
concentrations  comparing  CMV-seronegative  and  CMV-
seropositive individuals (data not shown). Latent CMV infection
Figure  2.    Percentage  of  vaccinees  protected  against  tetanus  and  diphtheria  and  geometric  mean  antibody
concentrations.  The percentages of vaccinees with tetanus (A)- or diphtheria (B)-specific antibody concentrations above (grey) or
below (black) 0.1 IU/ml, which is considered to be protective, are depicted in pie charts. Percentages and numbers of vaccinees are
indicated. The geometric mean concentrations (GMC) and 95% confidence intervals (CI) are indicated below the pies. Antibody
concentrations were measured by ELISA prior to and four weeks after the two consecutive vaccinations, which were administered at
a 5-year interval.
doi: 10.1371/journal.pone.0082967.g002
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[27,28].
Figure 3.  Correlation of antibody concentrations prior to and after vaccination.  Correlations of pre- (A) and post- (B) antibody
concentrations  for  the  first  and  second  vaccination  are  shown.  The  Spearman  correlation  coefficient  (rs)  and  the  p-value
(Spearman's rank correlation) are depicted for each diagram. The grey insert highlights individuals without protective diphtheria-
specific antibody levels for both doses of vaccine. p-values <0.05 are considered as significant.
doi: 10.1371/journal.pone.0082967.g003
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PLOS ONE | www.plosone.org 6 December 2013 | Volume 8 | Issue 12 | e82967Figure 4.  Correlations of tetanus- and diphtheria-specific antibodies prior to and after vaccination.  Correlations of tetanus-
and  diphtheria-specific  antibodies  prior  to  and  after  the  first  (A)  and  the  second  (B)  vaccination  are  shown.  The  Spearman
correlation coefficient (rs) and the p-value (Spearman´s rank correlation) are depicted for each diagram. The grey insert highlights
individuals with high tetanus-specific antibody concentrations despite low levels of diphtheria-specific antibodies. p-values <0.05 are
considered as significant.
doi: 10.1371/journal.pone.0082967.g004
Recall Responses to Tet/Dip Vaccination in Old Age
PLOS ONE | www.plosone.org 7 December 2013 | Volume 8 | Issue 12 | e82967Antibody concentrations following vaccination depend
on antigen-specific B but only modestly on Th2 cell
memory
To define which part of the adaptive immune response was
decisive  for  antibody  concentrations  after  vaccination,  we
determined  antigen-specific  T  cell  responses  as  well  as
antibody  secreting  cells  7  days  after  vaccination.  Generally,
more  tetanus-  than  diphtheria-specific  T  cells  were  detected
prior  to  and  after  the  vaccination  and  the  number  of  IL-5
secreting diphtheria-specific T cells was generally low (Figure
5A & B). Associations between antibody concentrations on day
28 and T cell and B cell responses on day 7 were analyzed.
While  antigen-specific  IFN-  γ  and  IL-5  production  did  not
correlate with antibody concentrations for tetanus (p=0.258 and
p=0.065),  there  was  a  correlation  between  antibody
concentrations  and  IL-5  (p=0.002),  but  not  IFN-γ  production
(p=0.036) for diphtheria. In contrast, there was a strong positive
relationship between the number of ASC and post-vaccination
antibody concentrations for both tetanus and diphtheria (Table
3).
Table 2. Correlations between immunological markers and
antibody  concentrations  prior  to  and  after  the  second
vaccination.
TETANUS        
  antibodies pre-vaccination antibodies post-vaccination
  rs p-value rs p-value
CD4+ naive -0.178 0.298 -0.080 0.644
CD4+ memory 0.156 0.364 0.036 0.835
CD4+ effector -0.023 0.892 0.119 0.488
CD8+ naive -0.042 0.807 0.053 0.760
CD8+ memory -0.004 0.981 -0.069 0.688
CD8+ effector 0.052 0.762 0.072 0.674
IL-6 -0.042 0.701 0.009 0.932
IL-10 0.155 0.151 0.053 0.633
CRP -0.266 0.014 -0.115 0.296
neopterin -0.077 0.477 0.015 0.889
kynurenine/tryptophan 0.049 0.652 0.212 0.052
DIPHTHERIA        
  antibodies pre-vaccination antibodies post-vaccination
  rs p-value rs p-value
CD4+ naive -0.141 0.413 -0.261 0.124
CD4+ memory 0.274 0.106 0.316 0.060
CD4+ effector -0.349 0.037 -0.072 0.675
CD8+ naive 0.106 0.540 0.066 0.703
CD8+ memory 0.201 0.241 0.188 0.273
CD8+ effector 0.199 0.244 -0.234 0.169
IL-6 0.055 0.614 0.118 0.283
IL-10 0.117 0.280 0.193 0.076
CRP -0.103 0.346 0.023 0.836
neopterin -0.027 0.805 0.093 0.396
kynurenine/tryptophan 0.028 0.796 0.116 0.291
Correlations of immunological parameters and antibody concentrations before and
after the second vaccination for tetanus and diphtheria. rs = Spearman correlation
coefficient; p-values ≤0.01 are considered significant.
doi: 10.1371/journal.pone.0082967.t002
The  number  of  antibody  secreting  cells  detected  in  the
periphery  7  days  after  booster  vaccination  (Figure  5  A&B)
reflects  stimulation  of  memory  B  cells,  which  have  been
generated by previous immunizations. Persons repeatedly not
responding  to  vaccination  against  diphtheria  (highlighted  in
grey in Figure 3B, right panel) did characteristically not have
detectable  numbers  of  antibody  secreting  cells  on  day  7
(Figure 5C) suggesting that their memory B cell pool was too
small  to  allow  a  protective  booster  response.  Similar  to  our
previous work [14] we saw a positive correlation of pre- and
post-vaccination  antibody  concentrations  (tetanus:  rs=0.311,
p=0.005; diphtheria: rs=0.668, p≤0.0001 for the first vaccination
and  tetanus:  rs=0.404,  p≤0.0001;  diphtheria:  rs=0.708,
p≤0.0001  for  the  second  vaccination).  In  summary,  these
results  demonstrate  that  antibody  responses  following
vaccination against tetanus and diphtheria greatly depend on B
cell  memory  and  pre-existing  plasma  cells  but  only  to  a  low
extent on Th2 and not on Th1 T cell memory in elderly persons.
Discussion
We investigated the level of protection against tetanus and
diphtheria in the elderly population and analyzed the immune
response  to  tetanus  and  diphtheria  following  two  doses  of
vaccine  applied  at  a  5-years  interval.  We  were  able  to
demonstrate that the levels of protection against tetanus and
diphtheria differ substantially in the elderly population.
Vaccination  history  was  highly  discordant  for  tetanus  and
diphtheria  with  only  31%  of  the  participants  having  received
their  last  vaccinations  against  both  antigens  simultaneously.
64% of the cohort had been vaccinated against tetanus in the
last 10 years. In contrast, only 33% of the cohort had received
vaccination against diphtheria in the last 10 years and 50% of
the  participants  did  not  know  whether  they  had  ever  been
vaccinated  against  diphtheria.  After  a  single  booster  shot  of
combined  tetanus/diphtheria  vaccine  most  individuals
developed protective antibody concentrations against tetanus
and diphtheria. However, 11% of our vaccinees did not have
protective  antibodies  against  diphtheria  4  weeks  after
vaccination.  After  5  years  10%  of  the  cohort  had  tetanus-
specific  antibodies  below  the  threshold  considered  to  be
protective and almost half of the participants had already lost
protective  diphtheria-specific  antibody  concentrations.  These
had  mostly  also  been  unprotected  at  the  time  of  enrollment
(see Figure 3A). It has previously been shown that adolescents
receiving one booster dose of tetanus and diphtheria vaccine
are  fully  protected  after  5  years,  but  that  antibody
concentrations decrease over time in adults under the age of
60 years leaving 40-50% unprotected against diphtheria after 5
years [29]. Taking into account that half of our cohort did not
have a documented history of diphtheria vaccination it seems
possible  that  they  were  never  vaccinated  against  diphtheria
and that the single shot applied with the low dose diphtheria
component  vaccine  (dT)  represents  insufficient  primary
immunization. The fact that a relatively high number of persons
lost  protective  immunity  within  5  years  supports  this
explanation.  It  is  not  yet  known  how  long  the  effect  of  the
second vaccination will last, but studies are on the way in our
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PLOS ONE | www.plosone.org 8 December 2013 | Volume 8 | Issue 12 | e82967Figure 5.  Antigen-specific cytokine secreting T-cells and antibody-secreting T cells.  A Box plots of tetanus-specific IFN-γ-
(left panel) and IL-5- producing (right panel) T cells and IgG-secreting B cells (right panel) as measured by ELISPOT before (day0)
and 7 days after vaccination. Boxes represent the 25th and 75th percentile and medians are indicated. Whiskers indicate the 5th
and 95th percentile. ** p<0.01 (Wilcoxon signed-rank test).
B Box plots of diphtheria-specific IFN-γ- (left panel) and IL-5- producing (right panel) T cells and IgG-secreting B cells (right panel)
as measured by ELISPOT before (day0) and 7 days after vaccination. Boxes represent the 25th and 75th percentile and medians
are indicated. Whiskers indicate the 5th and 95th percentile. ** p<0.01 (Wilcoxon signed-rank test).
C  Representative  examples  for  persons  without  (n=3)  or  with  high  (n=3)  diphtheria-specific  antibody  concentrations  following
vaccination Depicted are antibody concentrations 28 days after vaccination (black) and diphtheria-specific antibody secreting cells
(ASC) 7 days after vaccination (grey).
doi: 10.1371/journal.pone.0082967.g005
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a  relatively  large  number  of  persons  within  the  study  cohort
were  unprotected  for  at  least  part  of  the  5-year  observation
period  and  therefore  vulnerable  to  disease  in  the  case  of
exposure.
Our  study  protocol  followed  the  procedures  likely  being
utilized in general practice, that is, the application of a single
shot of combined vaccines containing tetanus and a reduced
dose of diphtheria after assessment of the vaccination status
for  tetanus,  which  was  relatively  well  documented  for  the
majority  of  the  cohort.  Our  data  demonstrated  that  this
approach  most  likely  leaves  large  parts  of  the  elderly
population  unprotected  against  diphtheria.  Lack  of  protection
against diphtheria may also represent a problem in respect to
other vaccinations, as diphtheria toxoid or derivatives thereof
are frequently used in conjugate vaccines. The relatively low
efficacy  of  pneumococcal  conjugate  vaccines  in  elderly
persons  may  thus  be  partly  explained  by  a  lack  of  carrier-
specific immune responses [30,31].
The  assumption  that  state-of-the-art  primary  immunization
was missing is also supported by the fact that no ASC were
found in the persons with the lowest antibody concentrations
and  the  very  good  correlation  between  ASC  and  antibody
responses. Our cohort thus partly seemed to have a too small
diphtheria-specific memory B cell pool and T cell help was only
borderline detectable in the form of low IL-5 production during
the response. In contrast there were sufficiently high numbers
of  tetanus-specific  ASC,  and  T  cell  help  was  obviously  not
necessary to activate them. It has been shown that age-related
changes of the T cell compartment, interpreted as indicators of
biological  aging  of  the  immune  system,  are  correlated  with
impaired immune responses to influenza vaccination [19,32,33]
and that the antibody response to pneumococcal vaccination is
decreased in frail elderly [34], which show increased levels of
inflammatory molecules, such as IL-6 and neopterin suggestive
of  “inflammaging”  [26,35,36].  However,  in  our  study  tetanus-
and  diphtheria-specific  antibody  concentrations  were
independent of inflammatory markers and the composition of
Table 3. Correlation between antibody concentrations and
cellular immune responses.
TETANUS      
    rs p-value
antibodies d28 IFN-γ secreting T cells 0.124 0.258
  IL-5 secreting T cells 0.201 0.065
  antibody secreting cells 0.446 <0.0001
DIPHTHERIA      
    rs p-value
antibodies d28 IFN-γ secreting T cells 0.228 0.036
  IL-5 secreting T cells 0.338 0.002
  antibody secreting cells 0.759 <0.0001
Correlations  of  antibody  concentrations  (day  28)  with  specific  IFN-γ  or  IL-5
secreting  T  cells  and  with  specific  antibody  secreting  cells  for  tetanus  and
diphtheria. rs = Spearman correlation coefficient; p-values ≤0.01 are considered
significant.
doi: 10.1371/journal.pone.0082967.t003
the T cell compartment. Due to the limited sample size and the
multiple  testing  when  investigating  the  dependence  of
concentrations on other characteristics the results should still
be interpreted with caution.
In  addition,  we  did  not  observe  a  significant  correlation
between  tetanus-  and  diphtheria-specific  immune  responses.
We therefore conclude that there is presumably not a general
“non-responder”  type  possibly  due  to  the  biological  aging
process, but that responses to booster vaccination depend on
pre-existing  plasma  cells  as  indicated  by  antibody
concentrations  prior  to  vaccination  and  B  cell  memory  as
indicated by specific ASC 7 days post vaccination.
The  proportion  of  persons  protected  against  tetanus  was
higher  in  our  present  cohort  than  in  previous  ones  [10,13],
which may be explained by the fact that the participants of the
present study were recruited at the Public Health Department
of the Federal State of Tyrol, where they went for regular visits.
This indicates that they were quite health conscious and aware
of  the  necessity  to  be  vaccinated  at  least  against  tetanus.
However,  vaccination  coverage  and  protection  was  low  for
diphtheria  even  in  this  population.  Discordant  levels  of
protection  against  tetanus  and  diphtheria  were  also
demonstrated in a serological survey in the UK, which showed
that 36% or 72% of a cohort older than 70 years had antibody
concentrations  below  0.1IU/ml  for  tetanus  and  diphtheria,
respectively  [37].  This  emphasizes  that  public  awareness
among doctors as well as patients regarding the necessity of
vaccination can be present for one vaccine but not for others
The  discrepancy  between  the  immunization  situation  for
tetanus  and  diphtheria  in  elderly  persons  will  have  to  be
addressed by future vaccination strategies. To achieve optimal
immunization  for  both  antigens  different  approaches  are
imaginable:  Firstly,  the  tetanus  component  could  be  applied
separately as in the past. This would have the disadvantage
that  the  rate  of  diphtheria  vaccination  would  presumably  still
drop  unless  public  awareness  of  the  necessity  of  diphtheria
vaccination was raised. The advantage of this approach would
be that proper primary immunization regimes against diphtheria
could  be  performed.  The  success  of  primary  immunization
relatively  late  in  life  remains  still  to  be  elucidated,  as  the
problem of memory generation late in life is well documented in
animal models [38,39]. An alternative approach might be the
use  of  different  adjuvants  for  the  three  component  vaccine.
Substances such as MF59 have been shown to work well in
seasonal as well as pandemic influenza vaccines [40–42] and it
might  therefore  be  possible  to  combine  a  sufficient  booster
effect for tetanus with the induction of a good primary response
for diphtheria.
Taken together our results demonstrate that even vaccines
as  well  known  and  common  as  the  combined  tetanus  and
diphtheria vaccine may not give satisfactory protection against
all  components  in  the  elderly  population.  This  represents  a
severe public health problem, which will have to be addressed
in the coming years.
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